Company News

Allergan Signs Deal with Acatvis

$66 billion deal shuts the door on Valeant-Ackman bid for Botox maker.

Author Image

By: Christine Esposito

Editor-in-Chief

It is Actavis plc—not Bill Ackman and Valeant Pharmaceutical—that will buy Allergan, the company behind Botox. The Dublin, Ireland and Parsippany, NJ-based pharma company and Allergan, Inc. announced a definitive agreement under which Actavis will acquire Allergan in a deal valued at approximately $66 billion. The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015. ...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters